Design of treatment trials for functional gastrointestinal disorders

Gut

Volumn 45, Issue SUPPL. 2, 1999, Pages

  Veldhuyzen Van Zanten, S J O ^a,f   Talley, N J ^g   Bytzer, P ^b   Klein, K B ^c   Whorwell, P J ^d   Zinsmeister, A R ^e  

^a Division of Gastroenterology   (Canada)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Intl Drug Development Consulting   (United States)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e MAYO CLINIC   (United States)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^g NONE

Author keywords

Clinical trial; Dyspepsia; Evidence based medicine; Functional dyspepsia; Functional gastrointestinal disorder(s); Irritable bowel syndrome; Outcome measures; Random allocation; Rome II; Study design

Indexed keywords

GASTROINTESTINAL AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; CYTOARCHITECTURE; DRUG EFFECT; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IRRITABLE COLON; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

CROSS-OVER STUDIES; GASTROINTESTINAL DISEASES; GUIDELINES; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0000448492     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. 1 Klein KB. Controlled treatment trials in the irritable bowel syndrome, a critique. Gastroentrology 1988;95:232-41.
2. 2 Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia. A systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-71.
3. 3 Talley NJ, Nyren O, Drossman DA, et al. The irritable bowel syndrome. Toward optimal design of controlled treatment trials. Gastroenterol Int 1993;6:189-211.
4. 4 Drossman DA, Richter JE, Talley NJ, et al (eds). The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. McLean, VA: Degnon Associates, 1994.
5. 5 Drossman DA, Thompson WG, Talley NJ, et al. Identification of subgroups of functional gastrointestinal disorders. Gastroenterol Int 1990;3:159-72.
6. 6 Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993;105:1378-86.
7. 7 Klauser A, Voderholzer WA, Knesewitsch PA, et al. What is behind dyspepsia? Dig Dis Sci 1993;38:147-54.
8. 8 Talley NJ, Meineche-Schmidt V, Parc P, et al. Omeprazole is efficacious in non-ulcer dyspepsia. Can J Gastroenterol 1998;12(suppl):70-71A.
9. 9 Lavori PW, Louis TA, Bailar JC III, et al. Designs for experiments. Parallel comparisons of treatment. N Engl J Med 1983;309:1291-8.
10. 10 Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med 1989;110:560-6.
11. 11 O'Donoghue DP, Dawson AM, Powell-Tuck Brown RL, et al. Double blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978;ii:955-7.
12. 12 Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20-2.
13. 13 Altman DG. Randomisation. BMJ 1991;302:1481-2.
14. 14 Rösch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987;22:161-4.
15. 15 Talley NJ, Silverstein MC, Agreus L, et al. AGA Technical review. Evaluation of dyspepsia. Gastroenterology 1988; 114(suppl A):582-95.
16. 16 Melzack R. The McGill Pain Questionnaire. Major properties and scoring methods. Pain 1975;1:277-99.
17. 17 Guyatt GH, Veldhuyzen van Zanten SJO, Feeney DH, et al. Measuring quality of life in clinical trials. A taxonomy and review. Can Med J Assoc 1989;140:1441-8.
18. 18 Guyatt GH, Feeney DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993:118:622-9.
19. 19 MacKenzie CR, Charlson ME. Standards for the use of ordinal scales in clinical trials. BMJ 1986;292:40-3.
20. 20 Jaeschke R, Singer J, Guyatt GH. A comparison of seven-point and visual analogue scales. Control Clin Trials 1990;11:43-51.
21. 21 Jacschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
22. 22 Dimenas H. Glise H, Ballerback B, et at. Well-being and gastrointestinal symptoms among patients referred to endoscopy due to suspected duodenal ulcer. Scand J Gastroenterol 1995;30:1046-52.
23. 23 El-Omar EM, Banerjee S, Wirz A, et al. The Glasgow Dyspepsia Severity Score. A tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol 1996;8:967-71.
24. 24 Veldhuyzen van Zanten SJO, Tygat KMAJ, Pollak PT, et al. Can severity of symptoms be used as outcome measures in trials of non-ulcer dyspepsia and Helicobacter pylori. J Clin Epidemiol 1993;46:273-9.
25. 25 Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome. The effect of hypnotherapy. Aliment Pharmacol Ther 1996;10:91-5.
26. 26 Hahn HA, Kirchdoerfer LJ, Fullerton S, et al. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:547-52.
27. 27 Patrick DL, Drossman DA, Frederick IO, et al. Quality of life questionnaire for patients with irritable bowel syndrome. Development and validation of a new measure. Dig Dis Sci 1998;43:400-11.
28. 28 Altman DG. Better reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
29. 29 Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986;105:429-35.
30. 30 Smith DG. Clemens J, Crede W, et al. Impact of multiple comparisons in randomized clinical trials. Am J Med 1987;83:545-50.
31. 31 Perniger TV. What is wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
32. 32 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
33. 33 Freiman JA, Chalmers TC, Smith H, et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 1978;299:690-4.
34. 34 Bero L, Rennie C. The Cochrane Collaboration. Preparing, maintaining and disseminating systematic reviews of the effects of health care. JAMA 1995;274:1935-8.